Sputnik V Demonstrates High 94.3% Efficacy and High Safety Profile During the Vaccination Campaign in Bahrain
A study evaluating the Russian Sputnik V coronavirus vaccine, conducted in Bahrain and enrolling over 5,000 subjects between February and May 2021, demonstrated safety and high efficacy of 94.3% beyond 14 days after administering the second dose. Results also show that 98.6% of all COVID-19 cases in those fully vaccinated (14 days after the second dose) were mild. Further results and advantages of the Sputnik V vaccine:
- 97.6% efficacy based on COVID-19 infection rate in Russians vaccinated with both components of Sputnik V between December 5, 2020, and March 31, 2021
- High safety data with no serious adverse events, allergies, deaths, or cerebral vein thrombosis (CVT)
- It is based on a well-established platform of human adenoviral vectors, which have been around for thousands of years
- 2 different vectors are used for the 2 shots of the vaccination, providing longer immunity
- Adenoviral vaccines have demonstrated safety, efficacy, and lack of negative long-term effects in over 250 clinical studies over 2 decades
- Sputnik V’s storage temperature allows it to be stored in a conventional refrigerator
- It is affordable, at $10 per shot “Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain.
This vaccine is one of a number of approved vaccines made available free of charge to citizens and residents in the Kingdom. Sputnik V continues to play an important role in the Kingdom’s ongoing and successful vaccination campaign, with 81% of the eligible population vaccinated so far,” said H.E Faeqa Saeed Al-Saleh, Bahrain’s Minister of Health.